Related Experiment Videos
Human adenovirus type 5 vectors expressing rabies glycoprotein
O K Yarosh1, A I Wandeler, F L Graham
1Department of Biology, McMaster University, Hamilton, ON, Canada.
Vaccine
|September 1, 1996
Summary
New recombinant adenovirus vectors (AdRG1.3 and AdRG4) show promise for oral rabies vaccination. These vectors express higher levels of rabies glycoprotein, inducing strong immune responses in animals, potentially aiding wildlife rabies control.
Area of Science:
- Veterinary Virology
- Vaccine Development
- Molecular Biology
Background:
- Rabies remains a global threat, necessitating effective wildlife vaccination strategies.
- Recombinant human adenovirus type 5 (Ad5) vectors expressing rabies glycoprotein (RG) have shown potential for rabies immunization.
- Improving Ad5 vector efficacy for oral rabies vaccines is crucial for disease control.
Purpose of the Study:
- To develop and compare novel Ad5-based recombinant vectors for enhanced oral rabies vaccination.
- To evaluate the expression levels of rabies glycoprotein (RG) and immunogenicity of new vectors.
Main Methods:
- Construction of two new replication-competent Ad5 vectors: AdRG1.3 and AdRG4.
- Comparison of RG expression in cell culture.
- Assessment of immunogenicity in animal models via parenteral and oral administration.
Main Results:
- AdRG1.3 and AdRG4 demonstrated higher RG expression in cell culture compared to the original AdRG1 vector.
- Both new vectors successfully induced high levels of anti-rabies antibodies in animals through parenteral and oral routes.
- AdRG1.3 showed potential as an effective vaccine vector in species with limited human Ad5 replication.
Conclusions:
- AdRG1.3 and AdRG4 represent improved Ad5-based vectors for rabies oral vaccination.
- These vectors effectively elicit immune responses, offering a promising tool for wildlife rabies management.
- AdRG1.3 may be particularly suitable for vaccinating species refractory to human adenovirus replication.